The China antiepileptics drugs market stood at around $0.82 Bn in 2022 and is projected to reach $1.32 Bn in 2030 with a CAGR of 2.3% for the year 2022-2030. Valproic acid and Lamotrigine are the top selling antiepileptic drugs in China. The market is segmented by generation and by distribution channel.
The China dermatology therapeutics market is projected to grow from $2.79 Bn in 2022 to $5.96 Bn in 2030 with a CAGR of 9.94% for the year 2022-2030. As China is one of the countries with a lot of focus on skin-related disorders and skincare routines, the market is projected to grow during the forecast period.
The increase in healthcare expenditure and the introduction of novel treatments for psoriasis in China are causing the China psoriasis market to grow during the forecast period. Major diseases in China include plaque psoriasis, nail psoriasis, and guttate psoriasis. The market is segmented by drug class, distribution channel, and route of administration.
The China telemedicine market is expected to witness growth from $4.88 Bn in 2022 to $20.59 Bn in 2030 with a CAGR of 19.7% for the year 2022-2030. China shows a lot of potential for the growth of telemedicine providers in the country. The market is segmented by products and services, type, specialty, and by delivery mode.
China Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is growing due to the increased cases of PNH cases in China. Although being a rare disease, its prevalence in China and the increased adoption of novel therapeutics to treat PNH are the major market drivers of the China PNH therapeutics market.